Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: A real-word evidence from the Czech Republic. Supplementary Material
Supplementary Figure 1 Changes between the ARIA frequency categories during the 3 years of therapy with Pollinex in the per-protocol (PP) and the intention-to-treat (ITT) populations
Supplementary Figure 2 Changes between the ARIA Severity categories during the 3 years of therapy with Pollinex in the per-protocol (PP) and the intention-to-treat (ITT) populations
Supplementary Figure 3 Proportion of patients with persistent and moderate-to-severe symptoms in those with and without concomitant asthma
Supplementary Figure 4 Average costs per patient with and without concomitant asthma
Supplementary Figure 5 Cumulative costs extrapolation beyond the horizon of the follow up according to different scenarios
Supplementary Table 1 Months of pollen season reported by individual patients starting Pollinex Tree (n=202)
Supplementary Table 2 Months of pollen season reported by individual patients starting Pollinex Rye (n=115)
Supplementary Table 3 Detailed frequency of symptomatic medication reimbursed by ATC group
Supplementary Table 4 The average costs per patient in all patients who started Pollinex therapy (intention-to-treat population)
Supplementary Table 5 The average costs per patient in the population of patients who completed the 3 years´ therapy with Pollinex Tree
Supplementary Table 6 The average costs per patient in the population of patients who completed the 3 years´ therapy with Pollinex Rye
Supplementary Table 7 The proportion of patients with concomitant asthma during the follow-up
Supplementary Table 8 ARTSS, ARMS, ACS, breathing difficulties and physician appointments in patients with concomitant asthma during the follow-up
Supplementary Table 9 Average costs per patient with and without concomitant asthma
Supplementary Table 10 Differences in outcome ARTSS score according to calendar year
